Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Current Deferred Revenue (2024)

Evommune (EVMN) has disclosed Current Deferred Revenue for 1 consecutive years, with $3.0 million as the latest value for Q4 2024.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $3.0 million in Q4 2024 year-over-year; TTM through Dec 2024 was $3.0 million, a N/A change, with the full-year FY2024 number at $3.0 million, changed N/A from a year prior.
  • Current Deferred Revenue was $3.0 million for Q4 2024 at Evommune.
  • In the past five years, Current Deferred Revenue ranged from a high of $3.0 million in Q4 2024 to a low of $3.0 million in Q4 2024.